Endothelin-1 levels in oral potentially malignant disorders and oral squamous cell carcinoma: a systematic review and meta-analysis

Endothelin-1 (ET-1) is a multifunctional vasoactive peptide implicated in tumor proliferation, invasion, and angiogenesis. Although ET-1 expression has been reported in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs), the magnitude and consistency of these associations remain unclear. We aim to systematically synthesize evidence on ET-1 levels in OSCC and OPMD compared with healthy controls. PubMed, Embase, CNKI, and Web of Science were searched up to April 30, 2026. Meta-analysis was performed using standardized mean difference (SMD). Heterogeneity was assessed with I 2 and Cochran Q tests. Publication bias was evaluated via funnel plots and Egger’s test. Study quality was evaluated using the Newcastle-Ottawa Scale (NOS). Eleven studies met the inclusion criteria; seven of these contributed quantitative saliva data to the meta-analysis, and four reported immunohistochemical (IHC) findings only. Patients with OSCC (Saliva: SMD = 1.76, 95% CI 0.77–2.75; I 2 = 89%) exhibited significantly higher ET-1 levels than healthy controls. Patients with OLP showed a pooled SMD of 0.31 (95% CI: -0.06–0.68; I 2 = 0%) and patients with OLK showed a pooled SMD of 1.42 (95% CI: 0.44–2.39 I 2 = 80%). IHC analysis showed significantly higher ET-1 positivity in OPMDs lesions and OSCC compared with normal mucosa; because the reported outcome metrics were not comparable, these findings were synthesized narratively. The level of salivary and serum ET-1 is significantly higher in OSCC than healthy control, suggesting that higher levels of ET-1 may be an important feature of OSCC. However, the evidence is limited by the small number of studies, very high heterogeneity, possible publication bias and very low certainty as assessed by GRADE, ET-1 should therefore be regarded as a hypothesis-generating candidate biomarker rather than a clinically validated test. More high-quality research is needed to verify these correlations and establish more reliable conclusions in the future.

Authors

Institutions

Publication Details

Journal
BMC Oral Health
Published
2026-11-18
DOI
https://doi.org/10.1186/s12903-026-10480-6
Primary Topic
Oral Health Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Endothelin-1 levels in oral potentially malignant disorders and oral squamous cell carcinoma: a systematic review and meta-analysis

Jincai Guo, Lijie Ren, Xueru Chen, Jiliang Yuan et al.
BMC Oral Health
Oral Health Pathology and Treatment
article

Endothelin-1 levels in oral potentially malignant disorders and oral squamous cell carcinoma: a systematic review and meta-analysis

Jincai Guo, Lijie Ren, Xueru Chen, Jiliang Yuan, Jifang Long
article en

Abstract

Endothelin-1 (ET-1) is a multifunctional vasoactive peptide implicated in tumor proliferation, invasion, and angiogenesis. Although ET-1 expression has been reported in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs), the magnitude and consistency of these associations remain unclear. We aim to systematically synthesize evidence on ET-1 levels in OSCC and OPMD compared with healthy controls. PubMed, Embase, CNKI, and Web of Science were searched up to April 30, 2026. Meta-analysis was performed using standardized mean difference (SMD). Heterogeneity was assessed with I 2 and Cochran Q tests. Publication bias was evaluated via funnel plots and Egger’s test. Study quality was evaluated using the Newcastle-Ottawa Scale (NOS). Eleven studies met the inclusion criteria; seven of these contributed quantitative saliva data to the meta-analysis, and four reported immunohistochemical (IHC) findings only. Patients with OSCC (Saliva: SMD = 1.76, 95% CI 0.77–2.75; I 2 = 89%) exhibited significantly higher ET-1 levels than healthy controls. Patients with OLP showed a pooled SMD of 0.31 (95% CI: -0.06–0.68; I 2 = 0%) and patients with OLK showed a pooled SMD of 1.42 (95% CI: 0.44–2.39 I 2 = 80%). IHC analysis showed significantly higher ET-1 positivity in OPMDs lesions and OSCC compared with normal mucosa; because the reported outcome metrics were not comparable, these findings were synthesized narratively. The level of salivary and serum ET-1 is significantly higher in OSCC than healthy control, suggesting that higher levels of ET-1 may be an important feature of OSCC. However, the evidence is limited by the small number of studies, very high heterogeneity, possible publication bias and very low certainty as assessed by GRADE, ET-1 should therefore be regarded as a hypothesis-generating candidate biomarker rather than a clinically validated test. More high-quality research is needed to verify these correlations and establish more reliable conclusions in the future.

BMC Oral Health
Hunan University of Traditional Chinese Medicine (CN)
Natural Science Foundation of Hunan Province
Good health and well-being
Oral Health Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon